NCT06592222View on ClinicalTrials.gov

A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies

CompletedOBSERVATIONAL
Enrollment

4

Participants

Timeline

Start Date

August 26, 2024

Primary Completion Date

March 3, 2025

Study Completion Date

March 3, 2025

Conditions
Multiple Myeloma
Interventions
DRUG

Elranatamab

BCMA-CD3 bispecific antibody

DRUG

Standard of care

Standard of care

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06592222 - A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies | Biotech Hunter | Biotech Hunter